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Objective: To study the practicality of the FITC-CSNRDARRC peptide ligand (containing 
the Cys–Ser–Asn–Arg–Asp–Ala–Arg–Arg–Cys nonapeptide) in diagnosing and monitoring 
bladder tumors.
Materials and methods: Between March 2011 and September 2011, 80 consecutive 
patients with radiographic abnormalities, localizing hematuria, other symptoms, or signs were 
  studied using the FITC-CSNRDARRC ligand, urinary cytology (UC), and fluorescence in situ 
  hybridization (FISH). The sensitivity and specificity of these three technologies were determined 
and compared. Cystoscopy and tissue biopsy were taken as the “gold standards” for bladder 
tumor diagnosis in this study.
Results: Twenty-nine out of 80 patients were diagnosed with a bladder tumor via histopathologi-
cal examination. The FITC-CSNRDARRC ligand was positive in 23 out of 29 bladder tumor 
patients and produced false negatives in six (20.69%) patients. The UC was positive in six out of 
29 bladder tumor patients and produced false negatives in 23 (79.31%) patients. The FISH was 
positive in 21 out of 29 bladder tumor patients and produced false negatives in eight (27.59%) 
patients. The overall sensitivity as verified by the FITC-CSNRDARRC ligand was much higher 
than in UC (79.31% versus 20.69%, P , 0.001) and was slightly higher than in FISH (79.31% 
versus 72.41%, P = 0.625). The sensitivity of FISH was significantly higher than that of UC 
(72.41% versus 20.69%, P , 0.001). Sensitivities of the FITC-CSNRDARRC ligand and UC 
by grade were 58.33% versus 8.3% for low-grade (LG) tumors (P = 0.031) and 94.12% versus 
29.41% for high-grade (HG) tumors (P = 0.003), respectively. The advantage was maintained 
in terms of the detection of invasive tumors between the FITC-CSNRDARRC ligand and UC 
(90.48% versus 23.81%, P = 0.001) as well as between FISH and UC (85.71% versus 23.81%, 
P = 0.003). The specificities for the FITC-CSNRDARRC ligand, UC, and FISH were 100%.
Conclusion: Results show that the FITC-CSNRDARRC ligand is a promising noninvasive tool 
for diagnosis and surveillance in patients suspected of having a new bladder tumor.
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Bladder tumors, accounting for 3.3% of all malignancies, are the ninth most common 
type of tumor worldwide.1,2 Bladder tumor patients are at high risk of recurrence 
and 7%–40% of patients will develop invasive tumors.3–5 The incidence of bladder 
tumors is also very high in China and has increased year on year. The main concern 
for doctors is in discerning which techniques should be used to diagnose bladder 
tumors in their early stages in order to improve the quality of the patients’ life. Early 
diagnosis and the monitoring of disease recurrence play a crucial role in the diagnosis 
of bladder tumors.
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Optical imaging has been increasingly used to probe 
protein function and gene expression in live animals.6 Peptide 
targeting of tumors is a new technique used for the diagnosis 
of bladder tumors. The CSNRDARRC ligand is the most 
recently developed diagnostic probe for the detection of 
bladder cancer.7
The CSNRDARRC sequence was selected as a synthetic 
peptide. In the study by Lee et al,7 the fluorescein-conjugated 
CSNRDARRC peptide selectively bound to human bladder 
tumor tissue, whereas only negligible binding to normal 
bladder tissue was observed. In our study, we made a fur-
ther test of the feasibility of the peptide in detecting tumor 
cells in urine, with the peptide showing little binding to the 
urinary cells of patients with inflammation, or to healthy 
individuals’ cells.
Knowledge concerning the genetic changes in blad-
der tumor cells provides the basis for the development of 
genetic urine tests.8 FISH proved to be an effective method 
for identifying chromosomal aberrations.9 In 2000, Sokolova 
et al10 developed what would become the first commercially 
available FISH probe set for bladder urothelial carcinoma 
detection in voided urine. The UroVysion FISH detection 
system (Abbott Molecular, DesPlaines, IL) received Food 
and Drug Administration (FDA) approval in 2001 for the 
detection of recurrent tumors in patients with a history of 
bladder cancer, while the use of the FISH technique is still 
in the clinical trial stage in China.
UC has a low sensitivity (,50%) but a high   specificity 
(.90%), particularly for LG tumors.11 Compared with UC, 
alternative methods, such as the bladder tumor antigen 
(BTA) test, the urinary nuclear matrix protein 22 (NMP22), 
surviving (SV), and telomerase tests have become avail-
able, but none of them has yet attained specificity equal to, 
or better than cytology.11,12 The sensitivity and specificity of 
the most used urinary tumor markers in detecting primary 
bladder cancer (ie, the tumor markers BTA, NMP22, SV, 
and telomerase) are far from satisfactory.13–16
Cystoscopy, tissue biopsy, and UC are three of the main 
technologies that are used for bladder tumor diagnosis, but 
all of them have issues.17,18 Cystoscopy and tissue biopsy 
are invasive techniques, and UC has a low sensitivity, so 
a simpler and higher sensitivity tumor diagnosis technique 
is needed. This study examines the FITC-CSNRDARRC 
ligand, which takes CSNRDARRC as the tumor marker and 
which has a high specificity for bladder tumor diagnosis. The 
aim of this study is to compare the specificity and sensitivity 
of the FITC-CSNRDARRC ligand, UC, and FISH, and to 
explore the clinical value of the FITC-CSNRDARRC ligand. 
Cystoscopy and tissue biopsy were taken as the “gold 
standards” for bladder tumor diagnosis in this study.
Materials and methods
Voided urine specimens from 80 consecutive patients (mean 
age, 67.27 years; standard deviation [SD], 3.25 years; range, 
41–88 years; males, 58 cases; females, 22 cases) with radio-
graphic abnormalities, localizing hematuria, other symptoms, 
or signs were obtained between March 2011 and September 
2011.
Urinary cytology
For each sample, 50 mL of voided urine was centrifuged at 
1300 rpm for 10 minutes at room temperature and then the 
supernatant was discarded. After pretreatment with 10% 
formaldehyde fixative, approximately 30 uL of the cell 
  pellet was dropped onto a standard glass slide. The glass 
slide was heated for 30 minutes at 56°C. After Papanicolaou 
or hematoxylin staining, the cell pellet was examined by 
microscope.
FISH analysis
Urine preparation for FISH
A hypotonic solution of potassium chloride (0.075M) was 
preheated in a constant temperature bath at 37°C for at least 
30 minutes. For each sample, 50 mL of voided urine was 
centrifuged at 1300 rpm for 10 minutes at room tempera-
ture and the supernatant was discarded. This was followed 
by incubation in a 5 mL hypotonic solution of potassium 
chloride for 30 minutes. Fresh Carnoy’s fixative (5 mL, 3:1 
by volume of methanol–glacial acetic acid) was added to 
the cell pellet, and the pellet was mixed and resuspended. 
The resulting pellet was centrifuged again and the superna-
tant was discarded. The process was repeated three times. 
Approximately 30 uL of cell pellet was dropped onto an 
APES-coated glass slide (3-aminopropyl-triethoxysilane), 
which was then air-dried and placed under a microscope in 
order to label a region with appropriate cellularity. The glass 
slide was heated for 1 hour at 56°C.
FISH
After pretreatment with 2 × sodium saline citrate (SSC) 
and pepsin at 37°C in a water bath with 10% formaldehyde 
at room temperature, the slides were dehydrated in 70%, 
80%, and 100% ethanol. Then, 2 uL of probe mixture, 
which was denatured at 73°C for five minutes, was added 
to each slide and sealed under a small glass coverslip, 
before overnight hybridization at 42°C. The procedure was 
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followed by washing in 0.4 × SSC/0.3% Nonidet (NP40) 
and 2 × SSC. After hybridization, the nuclei counterstaining 
was achieved with 4′,6-diamidino-2-phenylindole (DAPI). 
Slides were scored for hybridization signals on a cell-by-
cell basis using a fluorescence microscope.
In every case, the severity of the genetic alteration was 
defined as the percentage of cells showing cytogenetic abnor-
malities greater than the cut-off values (ie, the number of cells 
that showed a gain for at least two of the chromosomes 3, 7, 
and 17, or that showed complete deletion of the p16 (9p21) 
locus divided by the total enumerated cells, with the quotient 
multiplied by 100).
FITC-CSNRDARRC ligand
The procedure for the urine preparation for the FITC-CS-
NRDARRC ligand was the same as that of FISH.
The 15 mg/L solution of FITC-CSNRDARRC ligand in 
PBS was added to the glass slide and then it was incubated 
at 4°C for 1 hour. After being washed in PBS and air-dried, 
the nuclei counterstaining was achieved with DAPI. Slides 
were scored for hybridization signals on a cell-by-cell basis 
using a fluorescence microscope.
Statistical analysis
The sensitivities of the FITC-CSNRDARRC ligand, UC, 
and FISH were determined for patients with biopsy-proven 
urothelial carcinoma in the bladder, and the specificities 
were calculated for patients with no histological confirma-
tion of urothelial carcinoma or with negative cystoscopy 
  findings. McNemar’s test was used to determine the statistical 
difference among the use of the three techniques (FITC-
CSNRDARRC ligand, UC, and FISH). A P-value of ,0.05 
was considered to indicate statistical significance. The SPSS 
15.0 software package (SPSS, Chicago, IL) was used for 
statistical analyses.
Results
A total of 80 voided urine specimens were analyzed in this 
study: 58 from men and 22 from women. Twenty-nine 
patients were diagnosed as having a bladder tumor, of which 
two had pTa-LG disease, three had pTa-HG disease, two had 
pT1-LG disease, one had pT1-HG disease, three had pT2-LG 
disease, six had pT2-HG disease, five had pT3-LG disease, 
four had pT3-HG disease, and three had pT4-HG disease.
FITC-CSNRDARRC ligand
The FITC-CSNRDARRC ligand was positive in 23 out of 
29 bladder tumor patients and produced false negatives in 
six (20.69%) patients. The sensitivities and specificities of 
the FITC-CSNRDARRC ligand were 79.31% and 100%, 
respectively (Table 1).
The FITC-CSNRDARRC ligand was produced by TASH 
Biotechnology Co, Ltd (Shanghai, China). The CSNRDARRC 
peptide selectively bound to the nuclei of bladder tumor cells. 
The cells were determined as being positive if there were 
fluorescent probe signals in the nuclei (Figure 1).19
Urinary cytology
Of the 29 bladder tumor patients, six patients had a positive 
UC result and 23 had a false-negative UC result (79.31%). 
The sensitivities and specificities of the UC were 20.69% 
and 100%, respectively (Table 1).
Results were assessed as positive only in cases where 
malignancy was detected (Figure 2C). Suspicious and equivo-
cal cases were assessed as negative for the calculations of 
sensitivity and specificity.
FISH
The FISH showed positive results in 21 out of 29 bladder 
tumor patients and produced false negatives in eight (27.59%) 
cases. The sensitivities and specificities of the FISH were 
72.41% and 100%, respectively (Table 1).
Table 1 Detailed comparison of FITC-CSNRDARRC ligand, UC and FISH for the detection of bladder tumor in relation to tumor 
stages and tumor grades
Tumors UC FISH FITC-CSNRDARRC
n/N % n/N % n/N %
grade
  Low 1/12 8.3 6/12 41.67 7/12 58.33
  High 5/17 29.41 15/17 88.24 16/17 94.12
Stage
  pTa + pT1 1/8 12.5 3/8 37.5 4/8 50
  pT2 - pT4 5/21 23.81 18/21 85.71 19/21 90.48
Overall sensitivity 6/29 20.69 21/29 72.41 23/29 79.31
Overall specificity 51/51 100 51/51 100 51/51 100
Abbreviations: FISH, fluorescence in situ hybridization; UC, urinary cytology.
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Probes specific for the centromeres of chromosomes 
3, 7, 17, and for the p16 locus (GP Medical Technologies, 
Ltd, Beijing, China) were used in this study (Figure 3). Two 
DNA probes were mixed together as a set double-target FISH 
and paired as follows: chromosome 3 and p16 (rhodamine), 
chromosome 7 and 17 (FITC).
Statistical analysis
There is a significant difference in bladder tumor diagnosis in 
terms of the sensitivities of the FITC-CSNRDARRC ligand 
and UC (79.31% versus 20.69%, P , 0.001) (Tables 1 and 3), 
while no significant differences were found between the FITC-
CSNRDARRC ligand and FISH (79.31% versus 72.41%, 
P = 0.625) (Tables 1 and 3). A significant difference was found 
between the sensitivities of FISH and UC (72.41% versus 
20.69%, P , 0.001) (Tables 1 and 3). Meanwhile, the overall 
specificity for the FITC-CSNRDARRC ligand, UC, and FISH 
was 100%, which was not statistically significant.
Sensitivities of the FITC-CSNRDARRC ligand and 
UC by grade were 58.33% versus 8.3% for LG (P = 0.031) 
and 94.12% versus 29.41% for HG (P = 0.003) (Tables 1 
and 3), respectively, whereas the sensitivities of FISH and 
UC by grade were 41.67% versus 8.3% for LG (P = 0.063) 
(Tables 1 and 3) and 88.24% versus 29.41% for HG tumors 
(P = 0.006) (Tables 1 and 3), respectively. Moreover, the 
advantage is maintained for invasive tumors between the 
FITC-CSNRDARRC ligand and UC (90.48% versus 23.81%, 
P = 0.001) (Tables 1 and 3) as well as between FISH and UC 
(85.71% versus 23.81%, P = 0.003) (Tables 1 and 3).
Discussion
In the present study, we compared the performances of UC, 
FISH, and the FITC-CSNRDARRC ligand in the detection 
of bladder tumor cells in voided urine.
The high sensitivity obtained with the use of the FITC-
CSNRDARRC ligand in the 29 patients with bladder tumors 
was 79.31%, whereas with FISH it was 72.41%, compared 
with UC at only a 20.69% (both P , 0.001) detection rate. 
No significant difference was found between the FITC-
CSNRDARRC ligand and FISH (P = 0.625). As previously 
Figure  2  UC.  (A  and B )  Hematoxylin  stain,  (C  and D )  Papanicolaou  stain.   
(A, B and D) Three examples of normal cells and an example of tumor cells (C).
Note: Magnification ×400 (A and D) and ×200 (B and C).
Abbreviation: UC, urinary cytology.
Figure 3 FISH. Chromosome 3 and p16 (rhodamine), chromosome 7 and 17 (FITC). (A 
and B) Example of the same urine specimen cell, in which the percentage of FISH signals 
are greater than the cut-off value (CSP3, 23%; CSP7, 21%; gLPp16, 7%; CSP17, 9%). (C and 
D) Example of the same urine specimen cell, in which the percentage of FISH signals are 
lower than the cut-off value (CSP3, 3%; CSP7, 2%; gLPp16, 4%; CSP17, 2%).
Note: Magnification ×1000 (A–D).
Abbreviation: FISH, fluoresceuce in situ hybridization.
Figure 1 The FITC-CSNRDARRC ligand. (A and C) The nuclei counterstaining 
was achieved with DAPI. The light colored area in (B) is the nuclei. (D) DAPI was 
not used in the nuclei.
Notes: The CSNRDARRC peptide is selectively bound to the nuclei of bladder 
tumor cells. The bright dot pointed at by the arrows indicate where the peptides 
bind. Magnification ×1000 (A–D).
Abbreviations: DAPI, 4’, 6-diamidino-2-phenylindole.
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described, the sensitivity of FISH was higher for the detec-
tion of tumor cells in urine, compared with that of UC.20 In 
addition, the overall sensitivities of FISH and UC in this 
study were lower than those reported in several previous 
studies. Akkad et al12 obtained a sensitivity of 87.5% for 
FISH in contrast to the 72.41% found in our study. A possible 
explanation for this discrepancy is that there were different 
distributions of stage and grade in the analyzed samples in 
each study. The cytology had a sensitivity of 60%,12 while 
we obtained a low sensitivity of only 20.69%.
Generally, the specificity of FISH is very high when 
compared to that of other urine tests.21 For patients without 
bladder cancer, we found the same specificity of 100% for 
the FITC-CSNRDARRC ligand, FISH, and UC, which was 
not statistically significant.
In our study, six cases (false-negative rate = 20.69%) 
did not demonstrate the presence of carcinoma with the 
FITC-CSNRDARRC ligand, eight cases (27.59%) did not 
demonstrate this with FISH, and 23 cases (79.31%) showed 
no carcinoma presence with UC. The sensitivity can usu-
ally be improved by incorporating a washing cytology at 
different levels of the intubated ureter. However, even this 
method is not really reliable, with a false-negative rate of 
up to 39%.22 It has been previously suggested that a false-
negative result represents mostly LG urothelial lesions that 
do not shed tumor cells into the urine or that do not exhibit 
the chromosomal alterations that are detected through the 
assay procedure.
The positive predictive values (PPVs) of the FITC-CS-
NRDARRC ligand, UC, and FISH in our study were 100% 
(Table 2). The PPV that we found for FISH was slightly 
higher than that in the Marin–Aguileras study23 (100% 
versus 95.8%). The negative predictive value (NPV) of the 
  FITC-CSNRDARRC ligand was slightly higher than the 
FISH (89.47% versus 86.44%) and was distinctly better than 
the UC (89.47% versus 68.92%) (Table 2), which means that 
the FITC-CSNRDARRC ligand performed best in terms of 
excluding bladder tumors. The NPV of FISH was 72% in 
the studies mentioned above.
In the present study, two cases had a positive result with 
the FITC-CSNRDARRC ligand, while all other methods 
gave negative results. However, we cannot assume that the 
two cases were real false-positive results. Whether these 
cases can be considered as positives has yet to be clarified. 
The actual follow-up was too brief to give a reliable answer.24 
The two cases concern asymptomatic microscopic hematuria. 
We will be able to make a definite diagnosis via cystoscopy 
and tissue biopsy when the symptoms get worse.
In general, UC is a noninvasive method for detecting 
tumor cells in urine with high specificity. No noninvasive 
diagnostic method can fully take the place of histopathology.8 
Among these noninvasive examinations, the FITC-CSNRD-
ARRC ligand shows the closest results to histopathology.
In research on the CSNRDARRC ligand,19 fluorescence-
activated cell sorting and laser-scanning confocal microscopy 
were adopted. The results showed that the CSNRDARRC 
ligand had a dose-dependent affinity to bladder tumor cells, 
and that the binding site of the CSNRDARRC ligand was 
in the nuclei. As a screening test for bladder tumors, the 
CSNRDARRC ligand has characteristics of high affinity 
to bladder tumor cells. Therefore, the FITC-CSNRDARRC 
ligand has a certain rationality and feasibility for the study 
of bladder tumors.
In summary, the FITC-CSNRDARRC ligand shows 
superiority as a prognostic marker for patients suspected 
of having new or recurrent bladder tumors, has superior 
sensitivities and stable specificities, and is a noninvasive, 
low-cost, and simple experimental procedure. How this 
technology should be used to diagnose and monitor bladder 
tumors requires further study. In the future, we will investi-
gate the role of the FITC-CSNRDARRC ligand in both the 
grading and staging of bladder tumors. It is believed that the 
Table 2 The predictive values of three methods
Classification UC (%) FISH (%) FITC-CSNRDARRC (%)
PPV 1 1 1
NPV 68.92 86.44 89.47
Abbreviations: PPV, positive predictive value; NPV, negative predictive value.
Table 3 Statistical analysis obtained by FITC-CSNRDARRC ligand, UC and FISH for the detection of bladder tumor
P-value* (2-sided) Overall sensitivity
Tumor grades Tumor stages
Low High pTa + pT1 pT2 - pT4
UC vs FISH 0.063 0.006 0.500 0.001 0.000
UC vs FITC-CSNRDARRC 0.031 0.003 0.250 0.001 0.000
FISH vs FITC-CSNRDARRC 1 1 1 1 0.625
Note: *Statistically significant difference (P , 0.05), McNemar test.
Abbreviation: FISH, fluorescence in situ hybridization; UC urinary cytology.
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FITC-CSNRDARRC ligand will be a practical method for 
the detection and follow-up of bladder tumors and may aid 
in establishing the original diagnosis of the disease.
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